Angle PLC Announces Presentation of Data on Glioblastoma
ANGLE plc (OTCQX:ANPCY) presented promising data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells meeting. The study, using their Parsortix® system and CellKeep™ slides, demonstrated significant capabilities in detecting circulating tumor cells (CTCs) in glioblastoma patients.
Key findings showed CTCs were detected in 60% of patients, with CTC clusters observed in 78% of CTC-positive patients. The study revealed that 73% of subjects showed extracellular vesicles (EVs), highlighting the potential for liquid biopsy in monitoring glioblastoma. Notably, the system's label-free methodology successfully detected mesenchymal phenotype CTCs, which are typically undetectable using traditional CTC technologies.
ANGLE plc (OTCQX:ANPCY) ha presentato dati promettenti da uno studio concettuale su glioblastoma durante il 7th Advances in Circulating Tumour Cells meeting. lo studio, utilizzando il sistema Parsortix® e le diapositive CellKeep™, ha mostrato notevoli capacità nel rilevare le cellule tumorali circolanti (CTC) nei pazienti con glioblastoma.
I principali risultati hanno mostrato che le CTC sono state rilevate nel 60% dei pazienti, con grappoli di CTC osservati nel 78% dei pazienti CTC-positivi. Lo studio ha evidenziato che il 73% dei soggetti presentava vescicole extracellulari (EV), sottolineando il potenziale della liquid biopsy per monitorare il glioblastoma. In particolare, il metodo senza etichette del sistema ha rilevato con successo CTC di fenotipo mesenchimale, tipicamente non rilevabili con le tecnologie CTC tradizionali.
ANGLE plc (OTCQX:ANPCY) presentó datos prometedores de un estudio de prueba de concepto en glioblastoma en la 7th Advances in Circulating Tumour Cells. El estudio, utilizando su sistema Parsortix® y diapositivas CellKeep™, demostró capacidades significativas para detectar células tumorales circulantes (CTCs) en pacientes con glioblastoma.
Los hallazgos clave mostraron que las CTC se detectaron en el 60% de los pacientes, con conglomerados de CTC observados en el 78% de los pacientes CTC-positivos. El estudio reveló que el 73% de los sujetos presentó vesículas extracelulares (EV), destacando el potencial de la biopsia líquida para monitorear el glioblastoma. En particular, la metodología sin etiquetas del sistema detectó con éxito CTC de fenotipo mesenquimal, que típicamente no son detectables con tecnologías CTC tradicionales.
ANGLE plc (OTCQX:ANPCY)가 7th Advances in Circulating Tumour Cells 회의에서 교모세포종에 대한 개념 증명 연구의 유망한 데이터를 발표했습니다. 이 연구는 Parsortix® 시스템과 CellKeep™ 슬라이드를 사용하여 교모세포종 환자에서 순환 종양세포(CTC)를 탐지하는 데 있어 중요한 능력을 보여주었습니다.
주요 발견은 CTC가 환자의 60%에서 검출되었다, CTC 양성 환자의 78%에서 CTC 클러스터가 관찰되었다는 점입니다. 연구에 따르면 대상자의 73%가 외배엽 소체(Extracellular Vesicles, EV)를 보였으며, 이는 glioblastoma를 모니터링하기 위한 액체 생검의 가능성을 강조합니다. 특히 시스템의 라벨 프리(label-free) 방법론은 일반적으로 기존 CTC 기술로는 탐지하기 어려운 섬유모양(mesenchymal) 페놈의 CTC를 성공적으로 탐지했습니다.
ANGLE plc (OTCQX:ANPCY) a présenté des données prometteuses d’une étude conceptuelle sur le glioblastome lors de la 7e réunion Advances in Circulating Tumour Cells. L’étude, utilisant leur système Parsortix® et les diapositives CellKeep™, a démontré des capacités significatives à détecter les cellules tumorales circulantes (CTC) chez les patients atteints de glioblastome.
Les résultats clés ont montré que les CTC ont été détectées chez 60 % des patients, avec des grappes de CTC observées chez 78 % des patients CTC-positifs. L’étude a révélé que 73 % des sujets présentaient des vésicules extracellulaires (EV), soulignant le potentiel de la biopsie liquide pour surveiller le glioblastome. Notamment, la méthodologie sans étiquettes du système a détecté avec succès des CTC au phénotype mesenchymal, qui sont généralement indétectables avec les technologies CTC traditionnelles.
ANGLE plc (OTCQX:ANPCY) präsentierte auf der 7. Advances in Circulating Tumour Cells-Konferenz vielversprechende Daten aus einer Proof-of-Concept-Studie beim Glioblastom. Die Studie, die ihr Parsortix®-System und CellKeep™-Slides verwendete, zeigte signifikante Möglichkeiten bei der Detektion von zirkulierenden Tumorzellen (CTCs) bei Glioblastom-Patienten.
Wichtige Ergebnisse zeigten, dass CTCs bei 60% der Patienten nachgewiesen wurden, mit CTC-Clustern bei 78% der CTC-positiven Patienten beobachtet. Die Studie ergab, dass 73% der Probanden extrazelluläre Vesikel (EVs) aufwiesen, was das Potenzial der Flüssigbiopsie zur Überwachung des Glioblastoms hervorhebt. Bemerkenswert ist, dass die label-free Methodik des Systems erfolgreich mesenchymale CTCs nachweist, die typischerweise mit herkömmlichen CTC-Technologien nicht nachweisbar sind.
ANGLE plc (OTCQX:ANPCY) قدمت بيانات واعدة من دراسة إثبات المفهوم في الورم الدماغي النووي الخبيث (الغليوبلاستوما) خلال اجتماع 7th Advances in Circulating Tumour Cells. استخدمت الدراسة نظام Parsortix® والشرائح CellKeep™، وأظهرت قدرات كبيرة في اكتشاف الخلايا الورمية الدائرة (CTCs) لدى مرضى الغليوبلاستوما.
أظهرت النتائج الرئيسية أن CTCs تم اكتشافها لدى 60% من المرضى، مع ملاحظة تكتلات CTC في 78% من المرضى الإيجابيين لـ CTC. كشفت الدراسة أن 73% من المشاركين لديهم جسيمات خارجة الخلية (EVs)، مما يبرز إمكانات التشخيص السائل لمراقبة الغليوبلاستوما. جدير بالذكر أن المنهجية الخالية من الملصقات في النظام تمكنت من اكتشاف CTCات ذات النمط المتجدد (mesenchymal phenotype)، وهي عادة ما تكون غير قابلة للكشف بتقنيات CTC التقليدية.
ANGLE plc (OTCQX:ANPCY) 在第七届循环肿瘤细胞会议上公布了针对胶质母细胞瘤的概念验证研究的有希望的数据。该研究使用他们的 Parsortix® 系统和 CellKeep™ 幻灯片，展示了在检测循环肿瘤细胞（CTC）方面对胶质母细胞瘤患者具有显著能力。
关键发现显示 CTC 在 60% 的患者中被检测到，CTC 阳性患者中观察到 CT C 集簇的比例为 78%。研究还显示 73% 的受试者存在细胞外囊泡（EVs），强调了液体活检在监测胶质母细胞瘤方面的潜力。特别是，该系统的无标记方法成功检测到通常用传统 CTC 技术难以检测到的间充质表型 CTC。
- Successfully detected CTCs in 60% of glioblastoma patients, compared to ctDNA detection in less than 10% of cases
- Demonstrated ability to detect CTC clusters in 78% of CTC-positive patients
- Identified extracellular vesicles in 73% of subjects, enabling multi-analyte monitoring
- Unique capability to detect mesenchymal phenotype CTCs that traditional technologies miss
- Study limited to small sample size of only 15 patients
- Technology currently restricted to research use only, not approved for diagnostic procedures
CLINICAL study SHOWS DETECTION OF CTCs in glioblastoma Patients
GBM CTC isolation only possible with Parsortix label-free methodology
Data presented at the 7th ACTC meeting
GUILDFORD, SURREY / ACCESS Newswire / September 29, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of new data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells (ACTC) meeting, held 24-27 September 2025 in Thessaloniki, Greece.
The poster entitled 'Detection of circulating tumour cells from glioblastoma patients' blood samples' reports on data from 15 newly diagnosed, treatment-naïve glioblastoma (GBM) patients whose blood was processed using the Parsortix® system and CellKeep™ slides. This approach has the potential to allow for minimally invasive, repeatable monitoring in patients with GBM.
Key findings:
CTCs were detected in
60% of patients and CTC clusters, which are known to have high metastatic potential, were observed in78% of CTC-positive patients. This is particularly significant given that ctDNA is observed in less than10% of glioma patients possibly due to failure to cross the blood-brain barrier1All CTCs detected exhibited a mesenchymal phenotype, consistent with the biology of GBM, which would not be detectable using traditional CTC technologies that rely on cell surface markers to isolate CTCs
Extracellular vesicles (EVs) were observed in
73% of subjects, further supporting the potential of liquid biopsy for dynamic monitoring in GBMThe ability to harvest and analyse CTCs and EVs from a single blood sample opens new avenues for a multi-analyte, minimally invasive, real-time assessment of tumour biology, disease progression, and response to therapy in GBM patients
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are delighted to present our first data in GBM at the ACTC 2025 conference. These results demonstrate the capability of the Parsortix label-free system to capture and characterise CTCs in GBM where ctDNA approaches have struggled. This creates the opportunity to start monitoring GBM patients using proteomic and molecular biomarkers during their treatment, as well as support pharma companies developing new drugs for this cancer."
The poster is available on ANGLE's website: https://angleplc.com/resources/posters/
1. Bettegowda C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Jan Groen (Chair of the Board) | |
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper Sunila de Silva (Corporate Broking) Nigel Birks - Life Science Specialist Sales | +44 (0) 20 7220 0563 |
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The CellKeep slide is ANGLE's patented CTC harvesting technology, for high quality, reproducible and robust imaging of CTCs.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
About Glioblastoma
GBM is the most common and aggressive malignant brain tumour in adults, with an incidence of around 3-5 cases per 100,000 people annually worldwide. Prognosis remains poor despite treatment: median overall survival is typically 12-15 months and five-year survival rates are below
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
What were the key findings of ANGLE's (ANPCY) glioblastoma study presented at ACTC 2025?
How does ANGLE's Parsortix system perform compared to traditional CTC detection methods in glioblastoma?
What is the potential impact of ANGLE's technology for glioblastoma patients?
How many patients were included in ANGLE's glioblastoma study?
What is the current regulatory status of ANGLE's Parsortix system?
